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Aims Bindarit is an original compound with peculiar anti-inﬂammatory activity due to a selective inhi-
bition of a subfamily of inﬂammatory chemokines, including the monocyte chemotactic proteins MCP-1/
CCL2, MCP-3/CCL7, and MCP-2/CCL8. In this study, we investigated the effect of bindarit on neointima
formation using two animal models of arterial injury: rat carotid artery balloon angioplasty and wire-
induced carotid injury in apolipoprotein E-deﬁcient (apoE
2/2) mice.
Methods and results Treatment of rats with bindarit (200 mg/kg/day) signiﬁcantly reduced balloon
injury-induced neointima formation by 39% at day 14 without affecting re-endothelialization and
reduced the number of medial and neointimal proliferating cells at day 7 by 54 and 30%, respectively.
These effects were associated with a signiﬁcant reduction of MCP-1 levels both in sera and in injured
carotid arteries of rats treated with bindarit. In addition, in vitro data showed that bindarit (10–
300 mM) reduced rat vascular smooth muscle cell (VSMC) proliferation, migration, and invasion, pro-
cesses contributing to the injury-induced neointima formation in vivo. Similar results were observed
in hypercholesterolaemic apoE
2/2 mice in which bindarit administration resulted in a 42% reduction
of the number of proliferating cells at day 7 after carotid injury and in a 47% inhibition of neointima
formation at day 28. Analysis of the cellular composition in neointimal lesions of apoE
2/2 mice
treated with bindarit showed that the relative content of macrophages and the number of VSMCs
were reduced by 66 and 30%, respectively, compared with the control group.
Conclusion This study demonstrates that bindarit is effective in reducing neointima formation in both
non-hyperlipidaemic and hyperlipidaemic animal models of vascular injury by a direct effect on VSMC
proliferation and migration and by reducing neointimal macrophage content. All of these data were
associated with the inhibition of MCP-1 production.
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1. Introduction
Bindarit is an original indazolic derivative devoid of any
immunosuppressive effects and with no activity on arachido-
nic acid metabolism that was shown to have anti-
inﬂammatory activity in a number of experimental diseases
including nephritis, arthritis, pancreatitis, and colitis.
1–4
These pharmacological activities have been associated
with its ability to interfere with monocyte recruitment,
which has been ascribed to a selective inhibitory effect on
the monocyte chemotactic protein (MCP) subfamily of CC
inﬂammatory chemokines, including MCP-1/CCL2, MCP-3/
CCL7, and MCP-2/CCL8.
5 Phase II trials in patients with rheu-
matoid arthritis and lupus nephritis have shown that bindarit
was well tolerated and signiﬁcantly reduced urinary MCP-1
and albumin excretion in kidney disease.
6,7
It is well known that chemokines have a crucial role in
initiating and progressing neointima formation by control-
ling each step of the vascular remodelling in response to
various noxious stimuli.
8 Among pro-inﬂammatory CC che-
mokines, MCP-1 is receiving increasing attention. It has * Corresponding author. Tel: þ39 081 678424; fax: þ39 081 678403.
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blocking MCP-1 signalling decreases neointima hyperplasia
after balloon- and stent-induced injury in several animal
models;
9–11 similarly, catheter-based adenovirus-mediated
anti-monocyte chemoattractant gene therapy attenuates
in-stent neointima formation in monkeys.
12 Elevated circu-
lating levels of MCP-1 were observed in patients with reste-
nosis after coronary angioplasty.
13
The induction of MCP-1 not only correlates with macro-
phage accumulation but there is strong evidence for an
important role of MCP-1 in vascular smooth muscle cell
(VSMC) proliferation and migration,
14–16 processes that con-
tribute substantially to neointima formation after arterial
stenting and balloon angioplasty. In addition, it has been
shown that MCP-1 has a pivotal role in vein graft thickening
due to intima hyperplasia.
17 These data suggest that an anti-
inﬂammatory treatment based on the inhibition of MCP-1
may be an appropriate and reasonable approach for the pre-
vention of neointima formation.
Here, we investigated the effect of bindarit on neointima
formation in vivo using two well-known animal models of
arterial injury: rat carotid artery balloon angioplasty and
wire-induced carotid injury in apolipoprotein E-deﬁcient
(apoE
2/2) mice. In addition, the effects of bindarit on
VSMC proliferation and migration in vitro were also exam-
ined. The results provided in this study strongly support
the beneﬁcial effects of bindarit on the inﬂammatory/pro-
liferative processes leading to neointima formation.
2. Methods
2.1 Treatments
Bindarit, 2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy]
propanoic acid (MW 324.38), was synthesized by Angelini (Angelini
Research Center—ACRAF, Italy). Pharmacokinetic studies in rodents
show that bindarit is well absorbed when administered by oral
route, and it has a mean half-life of 9 h and, at dose regimen
used in this study, reaches plasma levels in the range of
150–450 mM (Product data sheet, Angelini Research Center).
Animals were treated with bindarit, suspended in 0.5% methylcel-
lulose aqueous solution, at the dose of 100 mg/kg given orally, by
gastric gavage, twice a day.
4 Rats were treated with bindarit from 2
days before angioplasty up to 14 days after, whereas apoE
2/2 mice
were treated from 1 week before endothelial denudation up to 28
days after. In each experiment, control animals received an equal
volume of methylcellulose (0.5 mL/100 g in rats; 0.1 mL/10 g in
mice). The concentrations of bindarit used for in vitro experiments
have been found previously to be effective at inhibiting MCP-1 syn-
thesis in human monocytes and umbilical vein endothelial cells.
5
2.2 Cell culture
Primary aortic VSMCs were isolated from the thoracic aorta of male
Wistar rats or female apoE
2/2 mice as described previously
16 and
grown in Dulbecco’s modiﬁed Eagle medium (DMEM; Cambrex Bio
Science) supplemented with L-glutamine, 10% foetal bovine serum
(FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin in a
humidiﬁed incubator at 378Ci n5 %C O 2. Before initiation of
assays, the VSMCs were switched into DMEM supplemented with
1% FBS for 48 h. Studies were performed with cells at passages 3–6.
2.3 Enzyme-linked immunosorbent assay
for MCP-1 protein
Cells were used after the induction of quiescence in 24-well plastic
culture plates at a density of 1.5   10
4 cells/well. The cells were
stimulated with platelet derived growth factor-BB (PDGF-BB;
10 ng/mL; R&D Systems) in the presence or absence of bindarit
(10–300 mM). After 6, 12, 24, and 48 h, media were collected, cen-
trifuged at 2000 g for 15 min at 48C, and supernatants were used for
enzyme-linked immunosorbent assay (ELISA) (OptEIATM,
Biosciences).
2.4 Proliferation assay
The cell proliferation assay was carried out using the MTT assay.
VSMCs were plated on 24-well plastic culture plates at the density
of 1.5   10
4 cells/well and then incubated with DMEM containing
PDGF-BB (10 ng/mL) for 48 h in the presence or absence of bindarit
(10–300 mM). The absorbance values were obtained with an ELISA
assay reader (630 nm).
2.5 Chemotactic migration and invasion
VSMC migration was evaluated using a modiﬁed Boyden chamber
(Corning 24 mm Transwell with 8.0 mm pore polycarbonate mem-
brane insert) coated with rat-tail collagen I (Sigma-Aldrich).
Biocoat Matrigel invasion chambers (with 8.0 mm pore) were used
according to the manufacturer’s instructions for invasion studies
(Becton–Dickinson). Brieﬂy, starved VSMCs were trypsinized and
pre-treated or not with bindarit (10–300 mM) for 2 h. 5   10
5 cells
were plated in the upper chamber in 150 mL of 1% FBS medium
with or without bindarit (10–300 mM) and the lower chamber was
ﬁlled with 600 mL of 1% FBS medium in the absence (untreated
cells) or presence of PDGF-BB 10 ng/mL. After 6 h for migration
assay or 48 h for invasion assay, the migrated cells were ﬁxed and
stained with haematoxylin. The number of migrated cells was
counted in eight randomly chosen ﬁelds per insert.
2.6 Animals
The investigation conforms to the Guide for the Care and Use of Lab-
oratory Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996), and Italian ministerial
authorization (DL 116/92) was obtained to carry out the experimen-
tation. Male Wistar rats (Harlan Laboratories) weighing 250 g and
8-week-old female apoE
2/2 mice (Charles River) were used for
the present study. Animals were housed at the Department of Exper-
imental Pharmacology, University of Naples Federico II.
2.7 Rat carotid balloon angioplasty
Rats were anaesthetized with an intraperitoneal injection of keta-
mine (100 mg/kg) (Gellini International) and xylazine (5 mg/kg)
(Sigma). Endothelial denudation of the left carotid artery was per-
formed with a balloon embolectomy catheter (2 F, Fogarty,
Edwards Lifesciences) according to the procedure well validated
in our laboratories.
18 Some animals were subjected to anaesthesia
and surgical procedure, without balloon injury (sham-operated
group). Rats were euthanized 1, 7, and 14 days after angioplasty.
Blood and carotid arteries were collected and processed as
described below.
2.8 Atherogenic murine model of vascular injury
ApoE
2/2 mice were fed an atherogenic diet (21% fat, 0.15% choles-
terol, 19.5% casein, wt/wt; TD88137, Mucedola) from 1 week before
until 4 weeks after carotid injury performed as described pre-
viously,
19 with minor modiﬁcation. Brieﬂy, mice were anaesthetized
as described above, and endothelial injury of the left common
carotid artery was performed with a 0.35 mm diameter ﬂexible
nylon wire introduced through the left external carotid artery and
advanced to the aortic arch. The endothelium was damaged by
passing the wire through the lumen of the artery three times.
Blood and carotid arteries were collected 7 and 28 days after wire
injury and processed as described below.
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Carotid arteries from rats or apoE
2/2 mice were ﬁxed by perfusion
with phosphate-buffered saline (PBS; pH 7.2) followed by PBS con-
taining 4% formaldehyde through a cannula placed in the left ventri-
cle. Parafﬁn-embedded sections were cut (6 mm thick) from the
approximate middle portion of the artery and stained with haema-
toxylin and eosin to demarcate cell types. Ten sections from each
carotid artery were reviewed and scored under blind conditions.
The cross-sectional areas of media and neointima were determined
by a computerized analysis system (LAS, Leica).
2.10 Proliferating cell nuclear antigen analysis
in injured rat carotid artery
Proliferating cell nuclear antigen (PCNA) analysis was used to quan-
tify the proliferative activity of cells at the injury sites and was per-
formed using monoclonal mouse anti-PCNA antibody (1:250, PC10,
Sigma) and biotinylated anti-mouse secondary antibody (1:400,
DakoCytomation). Slides were treated with streptavidin–HRP (Dako-
Cytomation) and exposed to diaminobenzidine chromogen (DakoCy-
tomation) with haematoxylin counterstain. The proliferating cell
number in the rat carotid arteries was scored in 10 ﬁelds for each
section, six sections from each carotid artery, and expressed as
the percentage of total medial and neointimal cells positive for
PCNA 7 days after angioplasty. The proliferating cell number in
the mouse apoE
2/2 carotid arteries was scored in 10 sections
from each carotid artery and expressed as the percentage of posi-
tive cells 7 days after wire injury.
2.11 MCP-1 immunohistochemistry
Rat carotid arteries (1, 7, and 14 days after angioplasty, or naive)
were snap-frozen in liquid nitrogen in OCT embedding medium
(Tissue Tek, Sakura Finetek). Ten cross-sections were cut (6 mm)
from the approximate middle portion of the artery and used for
MCP-1 detection. Sections were incubated with polyclonal goat
anti-MCP-1 antibody (1:50, R-17, Santa Cruz) diluted in blocking
buffer/0.3% Triton X-100 (MP Biomedicals) in PBS overnight before
being washed in TNT wash buffer (Tris–HCl, pH 7.5, 0.15 M NaCl,
and 0.05% Tween 20; Sigma). Sections incubated with goat non-
immune serum were used as negative controls. Subsequently, sec-
tions were incubated with biotinylated anti-goat secondary anti-
body (1:400, DakoCytomation) diluted in blocking buffer/0.3%
Triton X-100, washed in TNT wash buffer, treated with streptavi-
din–HRP, and exposed to diaminobenzidine chromogen with haema-
toxylin counterstain. The sections were photographed and the
images were stored in the image analysis system (LAS, Leica).
2.12 Enzyme-linked immunosorbent assay
Rat carotid artery was crushed into powder and resuspended in
100 mL of lysis buffer (20 mM HEPES, 0.4 mM NaCl, 1.5 mM MgCl2,
1 mM EGTA, 1 mM EDTA, 1% Triton X-100, and 20% glycerol) with pro-
tease inhibitors (1 mM DTT, 0.5 mM PMSF, 15 mg/mL Try-inhibitor,
3 mg/mL pepstatin-A, 2 mg/mL leupeptin, and 40 mM benzamidine).
After centrifugation at 13 000 g at 48C for 30 min, MCP-1 in the
supernatant was quantiﬁed using an ELISA kit (OptEIATM, Bio-
sciences). All measurements were performed in duplicate. The
values were corrected by protein concentrations measured by the
Bio-Rad protein assay kit (Bio-Rad).
Serum MCP-1 levels (1, 7, and 14 days after angioplasty) were also
measured in the same animals used above by ELISA (OptEIATM, Bio-
sciences). The results are expressed as nanograms per millilitre.
2.13 Western blot analysis
The levels of CD68 were evaluated in total extracts prepared from
two pooled rat carotid arteries. The extraction procedure was per-
formed as described above. Protein concentration was determined
by the Bio-Rad protein assay kit (Bio-Rad). Equivalent amounts of
protein (50 mg) from each sample were electrophoresed in an 8%
discontinuous polyacrylamide minigel. The proteins were trans-
ferred onto nitrocellulose membranes according to the manufac-
turer’s instructions (Bio-Rad). The membranes were saturated by
incubation with 10% non-fat dry milk in PBS/0.1% Triton X-100 for
3 h at room temperature and then incubated with anti-CD68
mouse antibody (1:1000; Serotec) or anti-b-actin (1:5000; Sigma)
mouse antibody overnight at 48C. The membranes were washed
three times with 0.1% Tween 20 in PBS and then incubated with anti-
mouse immunoglobulins coupled to peroxidase (1:1000; DakoCyto-
mation) for 1 h at room temperature. The immune complexes
were visualized by enhanced chemiluminescence (Amersham). Sub-
sequently, the relative intensities of the bands were quantiﬁed by
densitometric scanning of the X-ray ﬁlms with a GS-800 Imaging
Densitometer (Bio-Rad) and the computer program ‘Quantity One’
(Bio-Rad). Results are expressed as arbitrary units of CD68 protein
levels, normalized to protein levels of the housekeeping protein
b-actin.
2.14 Evaluation of re-endothelialization in injured
rat carotid artery
Re-endothelialization was assessed 2 weeks after balloon injury by
staining with Evans Blue dye (0.5 mL of 0.5% Evans Blue dye iv;
Sigma) as described previously.
20 Planimetric analysis with an
image analysis program (LAS, Leica) was performed.
Re-endothelialization was expressed as the percentage of
re-endothelialized area vs. the total denuded area. To verify that
the Evans Blue stain accurately depicted the presence or absence
of endothelium, sections of completely or partially
re-endothelialized carotid arteries (based on Evans Blue appear-
ance) were stained with antibody to von Willebrand factor (vWF,
Cytomation Dako) as described previously.
21
2.15 Immunohistochemisty analysis in injured
apoE
2/2 mouse carotid artery
Carotidarteriesweresnap-frozeninliquidnitrogeninOCTembedding
medium. Fifteen cross-sections were cut (6 mm) from the approxi-
mate middle portion of the artery and used for MCP-1, a-smooth
muscle actin (a-SMA), and macrophage detection by immunoﬂuores-
cence. For staining, the sections were processed as described above
and incubated with polyclonal goat anti-mouse MCP-1 antibody
(1:50, M-18, Santa Cruz) or rat anti-F4/80 monoclonal antibody
(1:50, clone BM8, Abcam) diluted in blocking buffer/0.3% Triton
X-100 (MP Biomedicals) in PBS overnight before being washed in
TNT wash buffer. Sections incubated with non-immune goat serum
or an isotype-matched control antibody were used as negative con-
trols.Subsequently,thesections wereincubatedwith1:75Texas Red-
donkey anti-goat IgG (Jackson ImmunoResearch Laboratories) or with
1:200 biotinylated anti-rat secondary antibody (DakoCytomation),
ampliﬁed with Tyramide Signal Ampliﬁcation Systems (PerkinElmer),
and revealed with streptavidin–FITC (1:50, DakoCytomation). Mono-
clonal anti-a-SMA FITC (1:250, clone 1A4, Sigma) was added in block-
ingbufferfor1 hbeforewashingasdescribedabove.DAPIwasusedto
identify nuclei. Images were taken using an AxioCam HRc video-
camera (Zeiss) connected to an Axioplan ﬂuorescence microscope
(Zeiss) using the AxioVision 3.1 software.
The neointimal areas stained for F4/80 were determined in digi-
tized images (ﬁve sections per mouse), and positive areas for
speciﬁc immunostaining were quantiﬁed (NIH Imaging; http://rsb
.info.nih.gov/ij). Data are expressed as the percentage of the
immunostained area per total neointimal area.
Serial carotid parafﬁn-embedded sections were cut (5 mm) and
used for detection of calponin (1:100, clone hCP, Sigma). Ten sec-
tions from each carotid artery were reviewed and scored under
blind conditions. The number of calponin-positive cells in neointima
was counted.
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triglyceride serum levels in apoE
2/2 mice
The concentrations of serum MCP-1, triglycerides, and cholesterol
were determined using enzymatic immunoassays according to the
manufacturer’s instructions (OptEIATM, Biosciences; Serum Trigly-
ceride Kit, Sigma; Cholesterol Assay Kit, Cayman Chemical).
2.17 Statistical analysis
Results are expressed as mean+SEM of n animals for in vivo exper-
iments and mean+SEM of multiple experiments for in vitro assays.
Student’s t-test was used to compare two groups and ANOVA (two-
tailed P-value) was used with the Dunnett post hoc test for multiple
groups using Graph Pad Instat 3 software (San Diego, CA, USA). The
level of statistical signiﬁcance was 0.05 per test.
3. Results
3.1 Effect of bindarit on rat VSMC proliferation
and migration
Initiation and maintenance of VSMCs proliferation is a critical
eventinthepathogenesisofneointimaformation.Asshownin
Figure 1A, bindarit at 100 and 300 mM signiﬁcantly inhibited
PDGF-BB-induced rat VSMCs proliferation by 27% (P , 0.05,
n ¼ 3) and 42% (P , 0.01, n ¼ 3), respectively. Similar
results were obtained with apoE
2/2 mice VSMC (data not
shown). Another key mechanism of neointima formation is
mitogen-mediated migration of VSMCs. Therefore, we evalu-
ated the effects of bindarit on PDGF-BB-induced rat VSMCs
chemotaxis. Bindarit inhibited signiﬁcantly (P , 0.01, n ¼
3) chemotactic migration at 100 and 300 mM by 45 and 50%,
respectively(Figure1B).Moreover,bindarit(100 mM)alsosig-
niﬁcantly reduced rat VSMCs invasion (by 30%, P , 0.01, n ¼
3,Figure1C)throughtheMatrigelbarrierwhichmimicsextra-
cellular matrix. Analysis of cell viability (.95%) demon-
strated that it was not affected by bindarit at the
concentrations used in this study (data not shown).
3.2 Effect of bindarit on MCP-1 production
To determine whether the anti-proliferative and anti-
migratory effects of bindarit were associated with MCP-1
inhibition, protein concentration of MCP-1 in the super-
natant of cultured rat VSMCs was determined by ELISA. As
shown in Table 1, stimulation of VSMCs with PDGF-BB
(10 ng/mL) caused a time-dependent increased release of
MCP-1 compared with that observed in unstimulated cells.
When rat VSMCs were stimulated with PDGF-BB in the pres-
ence of bindarit (10–300 mM), a concentration-related inhi-
bition of MCP-1 production was observed.
3.3 Effect of bindarit on neointima formation
in rat carotid arteries
To determine the efﬁcacy of a systemic treatment with bin-
darit for the limitation of neointimal hyperplasia, a rat
carotidarterialinjurymodelwasused.Aremarkableincrease
in the number of PCNA-positive cells was demonstrated in
both the media and neointima 7 days after injury in control
rats, which was signiﬁcantly reduced (P , 0.001, n ¼ 9) in
the bindarit-treated group (200 mg/kg/day) by 54 and 30%,
respectively (Figure 2A). Bindarit caused a signiﬁcant inhi-
bition of neointima formation by 39% (P , 0.01, n ¼ 19) at
day 14 compared with the control animals (Figure 2B).
Medial area (0.124+0.003 mm
2 in the sham group) was not
affected by both vascular injury and bindarit.
3.4 Effect of bindarit on monocytes/macrophages
inﬁltration in rat carotid arteries
Western blot analysis was performed to examine the effect
of bindarit on the carotid monocyte/macrophage content.
Monocyte/macrophage marker CD68 was highly expressed
in carotid arteries 14 days after angioplasty when compared
with that of sham-operated animals (Figure 2C). Bindarit
signiﬁcantly reduced CD68 levels as shown by relative densi-
tometric analysis.
3.5 Effect of bindarit on MCP-1 production
in rat carotid arteries
We observed a signiﬁcant time-dependent increase in MCP-1
production in the injured arteries at 1, 7, and 14 days after
Figure 1 (A) Effect of bindarit (10–300 mM) on rat VSMC proliferation,
(B) migration, and (C) invasion performed as described in Section 2. Results
are expressed as mean+SEM from three separate experiments. *P , 0.05,
**P , 0.01 vs. platelet derived growth factor-BB (PDGF-BB); 88P , 0.01,
888P , 0.001 vs. unstimulated cells.
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animals (Figure 2D). Bindarit was able to inhibit the MCP-1
protein expression throughout the time course considered,
by 31% (P , 0.05; n ¼ 5), 38% (P , 0.05; n ¼ 5), and 49%
(P , 0.001; n ¼ 5) at 1, 7, and 14 days after injury, respect-
ively. In the contralateral carotid artery, no signiﬁcant
changes were observed throughout the observation period
compared with those measured in sham-operated animals.
In carotid arteries from naive animals, the levels of MCP-1
measured were 0.74+0.34 ng/mg (n ¼ 5).
3.6 Effect of bindarit on MCP-1 localization
in rat carotid arteries
Non-injured carotid arteries lacked immunoreactivity for
MCP-1, whereas injured arteries stained strongly for MCP-1
Figure 2 (A) Photomicrographs showing the effect of bindarit (200 mg/kg/day) on PCNA-positive cells in rat carotid arteries at day 7 after injury (magniﬁcation
 400). Results are expressed as mean+SEM of the percentage of total medial and neointimal cells positive for PCNA as described in Section 2, where n ¼ 9 rats for
each group. ***P , 0.001 vs. control group. (B) Photomicrographs showing the effect of bindarit (200 mg/kg/day) on neointima formation in rat carotid arteries
14 days after balloon injury (magniﬁcation  100). Results are expressed as mean+SEM, where n ¼ 15–19 rats. **P , 0.01 vs. control group. (C) Effect of bindarit
(200 mg/kg/day) on monocyte/macrophage marker CD68 protein expression in carotid arteries 14 days after angioplasty. Equal loading was conﬁrmed by b-acting
staining. Results are expressed as mean+SEM of three separate experiments. **P , 0.01 vs. control group. (D) Effect of bindarit (200 mg/kg/day) on MCP-1
expression in rat carotid arteries 1, 7, and 14 days after balloon injury evaluated by ELISA. Results are expressed as mean+SEM of MCP-1 levels normalized
with protein concentrations, where n ¼ 5 (see Section 2). *P , 0.05; ***P , 0.001 vs. control group; 888P , 0.001 vs. sham-operated animals.
Table 1 Effect of bindarit on MCP-1 production by platelet derived growth factor-BB (PDGF-BB)-stimulated VSMCs
MCP-1 (ng/mL)
6 h 12 h 24 h 48 h
Unstimulated cells 0.32+0.02 3.2+0.21 18.5+0.9 34.1+1.4
PDGF-BB 10 ng/mL 3.1+0.188 20.8+1.5888 59.6+0.488 142.6+2.888
PDGF-BB 10 ng/mL þ bindarit 10 mM 3.0+0.2 18.3+1.2 50.9+1.2** 128.0+3.7**
PDGF-BB 10 ng/mL þ bindarit 30 mM 1.5+0.1** 13.7+0.5** 42.8+0.6** 87.3+1.7**
PDGF-BB 10 ng/mL þ bindarit 100 mM 1.3+0.2** 11.9+0.4** 34.0+1.0** 80.1+1.8**
PDGF-BB 10 ng/mL þ bindarit 300 mM 0.8+0.1** 4.8+0.5** 29.3+1.1** 72.1+1.3**
Results are expressed as mean+SEM of three separate experiments performed in triplicate.
88P , 0.01 vs. unstimulated cells.
**P , 0.01 vs. PDGF-BB.
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MCP-1-positive staining was detectable in media of injured
vessel from days 1 up to 14 and in neointimal cells at days
7 and 14. MCP-1 localization was not modiﬁed by bindarit,
whereas the drug treatment resulted in a lower MCP-1
expression in both media and neointima (Figure 3).
3.7 Effect of bindarit on re-endothelialization
in rat carotid arteries
Evans Blue staining identiﬁes segments of injured carotid
arteries that have not been re-endothelialized. As shown
in Figure 4, the presence of intact endothelium in the
carotid artery of naive rats was demonstrated by the
absence of Evans Blue staining. Immunohistochemical stain-
ing with antibody to vWF veriﬁed the presence of endo-
thelium. In contrast, the entire area of the artery
harvested 1 day after injury was stained by Evans Blue.
The absence of positive staining with antibody to vWF con-
ﬁrmed the observation. Analysis of samples at 2 weeks
from angioplasty showed that bindarit treatment did not
affect re-endothelialization of arteries when compared
with control animals.
3.8 Effect of bindarit on MCP-1 serum levels
A time-dependent increase in MCP-1 serum concentration
was observed in rats subjected to angioplasty (Table 2). Bin-
darit caused a signiﬁcant inhibition of MCP-1 serum levels at
day 1 by 20% (P , 0.05, n ¼ 10) and at days 7 and 14 by 30%
(P , 0.001, n ¼ 10) compared with their respective control
groups. In naive animals, the MCP-1 serum level was
29.4+3.0 ng/mL (n ¼ 5).
3.9 Effect of bindarit on neointima formation
in apoE
2/2 mice
To evaluate the effect of bindarit after arterial injury in
hyperlipidaemic animals, carotid endothelial denudation
was performed in apoE
2/2 mice fed an atherogenic diet.
Seven days after injury, the number of PCNA-positive cells
was signiﬁcantly reduced (42%; P , 0.05, n ¼ 10) by
treatment with bindarit (200 mg/kg/day) compared with
control mice (Figure 5A). Neointimal area was reduced by
47% in apoE
2/2 mice treated with bindarit compared with
control mice 28 days after injury (Figure 5B). Moreover,
the apoE
2/2 mice receiving bindarit showed a 66% reduction
in the relative content of F4/80-positive macrophages and a
30% reduction in the number of VSMCs in neointimal lesion
(Figure 5C and D).
Injured carotid arteries stained strongly for MCP-1 detect-
able in media and neointima 28 days after injury.
Co-localization of MCP-1 and a-actin was evident in both
media and neointima. MCP-1 localization was not modiﬁed
by bindarit, but again the drug reduced both medial and
neointimal MCP-1 expression (Figure 5E).
Total cholesterol levels did not differ between groups
(1036+38 mg/dL in bindarit-treated group, n ¼ 10 vs.
1167+50 mg/dL in control group, n ¼ 10), whereas trigly-
ceride levels were signiﬁcantly lower (P , 0.05) in bindarit-
treated animals (191.6+21.3 mg/dL, n ¼ 10) than in the
control group (260.7+20.6 mg/dL, n ¼ 10). Moreover, bin-
darit caused a signiﬁcant inhibition (P , 0.01) of MCP-1
serum levels by 42% (131.0+15.6 pg/mL in bindarit-treated
group, n ¼ 10 vs. 224.8+28.3 pg/mL in control group, n ¼
10; P , 0.01).
4. Discussion
The results provided in this study show that bindarit given
systemically signiﬁcantly reduced neointimal formation in
animal models of arterial injury by inhibiting VSMC prolifer-
ation/migration, and macrophage inﬁltration; these effects
correlated with a reduction in MCP-1 synthesis.
Bindarit is an original compound selected by screening a
series of indazolic derivatives endowed with peculiar anti-
inﬂammatory activity associated with a selective inhibition
of a subfamily of CC inﬂammatory chemokines, including
MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8, showing no
effect on other CC and CXC chemokines such as MIP-1a/
CCL3, MIP-1b/CCL4, MIP-3/CCL23, RANTES/CCL5, and IL8/
CXCL8.
1–5
Figure 3 Immohistochemical localization of MCP-1 expression in rat carotid arteries 1, 7, and 14 days after angioplasty.
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neointimal formation, mainly due to proliferation and
migration of VSMCs, that causes a clear narrowing of the
vessel lumen.
Neointima formation contributes to the development of
restenosis after coronary artery angioplasty, with or
without stenting, in which a pivotal mechanism is rep-
resented by the loss of differentiation of VSMCs that were
Figure 5 (A) Photomicrographs showing the effect of bindarit (200 mg/kg/
day) on PCNA-positive cells in apoE
2/2 mice 7 days after injury (magniﬁ-
cation  400). Results are expressed as mean+SEM of the percentage of
total PCNA-positive cells as described in Section 2, where n ¼ 10 rats for
each group. *P , 0.05 vs. control group. (B) Photomicrographs showing the
effect of bindarit (200 mg/kg/day) on neointima formation in apoE
2/2
mice 28 days after carotid injury (magniﬁcation  100). Results are expressed
as mean+SEM, where n ¼ 10 for each group; **P , 0.01 vs. control group.
(C) Photomicrographs showing the effect of bindarit (200 mg/kg/day) on
macrophage content in carotid arteries 28 days after injury (magniﬁcation
 400). Results are expressed as mean+SEM of the percentage of F4/80
immunostained area per total neointima area, where n ¼ 10 for each
group; ***P , 0.001 vs. control group. (D) Photomicrographs showing the
effect of bindarit (200 mg/kg/day) on neointimal VSMCs content in carotid
arteries 28 days after injury (magniﬁcation  100). Results are expressed as
mean+SEM of the calponin-immunostained cell number, where n ¼ 10 for
each group; *P , 0.05 vs. control group. (E) Immunoﬂuorescence visualiza-
tion of a-SMA (green) and MCP-1 (red) in mouse carotid arteries 28 days
after injury. DAPI (blue) was used to locate nuclei. Co-localization of MCP-1
and a-actin (yellow) was evident in some cells in both media and neointima
(magniﬁcation  200).
Figure 4 Extent of re-endothelialization in injured carotid arteries evalu-
ated by Evans Blue staining. Representative arteries harvested from naive
animals, as well as 1 and 14 days after carotid injury in vehicle- or bindarit-
treated rats. Evans Blue staining identiﬁes segments of each artery that have
not been recovered by endothelium. Immunohistochemical staining with anti-
body to vWF veriﬁed the presence of endothelium. Re-endothelialization was
expressed as the percentage of re-endothelialized area vs. the total denuded
area (bottom panel) (n ¼ 5).
Table 2 Effect of bindarit on MCP-1 serum levels in rats
Group MCP-1 (ng/mL)
1-day 7-day 14-day
Sham-operated 37.1+2.4 35.4+1.2 32.8+2.7
Control 69.2+3.588 51.4+2.288 53.7+3.988
Bindarit (200 mg/
kg/day)
55.6+3.0* 36.2+2.4*** 37.2+2.1***
Results are expressed as mean+SEM, where n ¼ 5–10 rats per each
time point considered.
88P , 0.01 vs. sham-operated animals.
*P , 0.05.
***P , 0.001 vs. control group.
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22 It is well known that
among pro-inﬂammatory CC chemokines, MCP-1 is impli-
cated in all these processes and the source of this chemo-
kine is likely to include the major cells in injured arteries,
such as endothelial cells, VSMCs, and macrophages.
23
In injured carotid arteries from animals treated with bin-
darit, a signiﬁcant inhibition of neointima formation associ-
ated with a reduced MCP-1 production was observed.
Bindarit did not modify MCP-1 localization but reduced
MCP-1 expression in both media and neointima. Moreover,
bindarit caused signiﬁcant inhibition of MCP-1 serum
levels. Increased levels of circulating MCP-1 in animals sub-
jected to vascular injury are in keeping with an active role
for this cytokine in tissue pathogenesis and correlate with
epidemiological evidence showing higher MCP-1 plasma
levels associated with human restenosis.
13,24
Bindarit showed both in vivo and in vitro antiproliferative
effects. For example, bindarit diminished the number of
PCNA-positive proliferating cells in the media and intima
7 days after angioplasty, concomitantly with the
beginning of neointimal formation, without affecting
re-endothelialization evaluated 14 days after injury.
In vitro studies further demonstrated inhibitory effects of
bindarit on PDGF-BB-stimulated rat VSMC proliferation and
migration. These effects were associated with a signiﬁcant
and concentration-related inhibition of MCP-1 amounts
measured in the supernatants of stimulated cells treated
with bindarit. It is well known that MCP-1 activity is in
part due to recruitment of monocytes/macrophages that
are responsible for local production of cytokines, but
MCP-1 may also directly induce VSMC proliferation and
migration through cell cycle proteins and intracellular pro-
liferative signals.
14–16
Our results also showed that bindarit reduced monocytes/
macrophages recruitment in injured rat carotid arteries.
The rat balloon angioplasty model could be considered
ideal to study the proliferation of VSMCs in vivo; however,
it is not an ideal model for the study of monocytes/macro-
phages recruitment, considering the injury is performed in
a non-atherosclerotic arterial bed.
25,26
It is well known that hypercholesterolaemia, a potent
trigger of vessel wall inﬂammation in atherosclerosis,
induces MCP-1 expression in VSMCs and upregulates CCR2
in human monocytes, enhancing monocyte recruitment
after arterial injury and thus mediates the exacerbation of
neointimal growth.
27–29 In our experiments, no clear ather-
osclerotic lesions were detectable in the aortic root of mice
28 days after injury. However, we and others have demon-
strated that lymphocytes already reside into the adventitia
of arterial wall of apoE
2/2 mice even before the onset
atherosclerosis.
30,31 In this light, the hyperlipidaemic mice
tool represents a step forward to the rat balloon angioplasty
model, allowing us to study the effect of bindarit in the
contest of increased vascular inﬂammation. Our results
clearly demonstrated that bindarit reduced neointima for-
mation by reducing proliferating rate and macrophage inﬁl-
tration, effects associated with a reduced expression of
MCP-1 in injured vessels. In hypercholesterolaemic rabbits,
gene transfer of a plasmid coding for a mutant form of
MCP-1 appeared to reduce neointima formation after
balloon injury, mainly inhibiting macrophage inﬁltration to
the injured vessels.
32 Similarly, in hypercholesterolaemic
apoE
2/2 mice also deﬁcient in CCR2, neointimal lesions
after wire injury of the carotid artery were diminished and
showed a marked reduction in macrophage content com-
pared with apoE
2/2/CCR2
þ/þ mice.
33
In conclusion, this study demonstrates that bindarit is
effective in reducing neointima formation both in a non-
hyperlipidaemic animal model of vascular injury, mainly by
a direct effect on VSMC proliferation/migration, and in
hyperlipidaemic animals by reducing macrophage
inﬁltration.
The exploitation of the chemokine system as a drug target
in vascular pathology has relied mainly on the development
of receptor antagonists and blocking antibodies.
23 However,
the attempt to block chemokines and their receptors in
humans is more complex.
6 Here, we report the use of bin-
darit, an inhibitor of MCP-1 synthesis, as a potentially
viable approach to control neointimal formation even if
the clinical effects cannot be immediately predicted and
further experiments, as well as clinical trials, will be
necessary.
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